Toyama Oncothermia Study for Intractable Malignant Brain Tumor

Toyama Oncothermia Study for Intractable Malignant Brain Tumor - Toyama Oncothermia Study for Intractable Malignant Brain Tumor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022478

Enrollment

Registered

2016-05-26

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant brain tumor

Interventions

Oncothermia 80-W therapy for 60 min/day Twice/week 8 therapies/course

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 years old or older 2) Histologically diagnosed as malignant brain tumor 3) Intractable patients who do not respond to standardized therapy or high-risk patients who cannot undergo standardized therapy 4) Expected survival longer than 2 months 5) Informed consent obtained from the patients themselves

Exclusion criteria

Exclusion criteria: 1) Infected patients 2) Malnutrition 3) Severe comorbid such as heart disorders, colon dysfunction, lung fibrosis, uncontrolled diabetes mellitus, and chronic renal failure 4) Psychological disorders 5) Pregnancy 6) Others

Design outcomes

Primary

Measure	Time frame
1) Outcome Clinical outcome is assessed using RECIST (Response Evaluation Criteria in Solid Tumors) on MRI and is categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). 2) Incidence of the following adverse events a) General condition Fatigue, fever, headache, hypotension, bradycardia, respiratory distress, allergic reaction b) Local condition Local pain, dermatitis, skin necrosis c) Laboratory examinations RBC, Hb, WBC, platelet, ALT (GOT), AST (GPT), LDH, T-bil, Cr d) Others	—

Measure

Time frame

1) Outcome Clinical outcome is assessed using RECIST (Response Evaluation Criteria in Solid Tumors) on MRI and is categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). 2) Incidence of the following adverse events a) General condition Fatigue, fever, headache, hypotension, bradycardia, respiratory distress, allergic reaction b) Local condition Local pain, dermatitis, skin necrosis c) Laboratory examinations RBC, Hb, WBC, platelet, ALT (GOT), AST (GPT), LDH, T-bil, Cr d) Others

—

Secondary

Measure	Time frame
1) Karnofsky performance status (KPS) 2) Pre- and post-treatment radiological findings a) MRI b) MRS c) 201Tl SPECT d) 16F-FDG PET	—

Countries

Japan

Contacts

Public ContactYoshiko Takado

Toyama University Hospital Neurosurgery

nsurgery@med.u-toyama.ac.jp076-434-7348

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026